Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round

Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round

  • Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fund
  • Alentis is focused on the development of breakthrough treatments for fibrotic diseases and associated cancers

Paris, France, 15 June 2021 – Jeito Capital (Jeito), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today announces that it has become a key investor as part of a $67 million Series B financing round in Alentis Therapeutics (Alentis). The Swiss biotech company, a spin-off of French Inserm with R&D in Strasbourg, France, is developing breakthrough therapies for patients suffering from fibrotic diseases and associated cancers.

Proceeds from the financing round will be used for proof-of-concept clinical trials of Alentis’ first-in-class assets, uniquely targeting fibrosis pathways for the treatment of life-threatening advanced liver and kidney fibrosis as well as associated cancers. Alentis expects to initiate its first clinical trial by the end of 2021.

Jeito’s investment aims to enable Alentis to accelerate the clinical pathway for various indications, with the potential to provide life-changing treatments to severely ill patients who have no other options. The investment will also give the Company the opportunity to expand its pipeline and explore further indications, including fibrotic associated cancers.

The financing round brings in Jeito Capital and Morningside Venture Investments alongside existing investors BioMed Partners, BB Pureos Bioventures, Bpifrance, High-Tech Gründerfonds and Schroders Capital. Following the fundraise, Rafaèle Tordjman, Founder and CEO of Jeito Capital, will join Alentis’ Board of Directors.

This is Jeito’s fifth investment since launching its fund in 2020. With more than €250 million under management, Jeito Capital is building a strong and diversified portfolio in biotech and biopharma companies based in Europe with global reach focused on the treatment of life-threatening diseases. Previous investments include French companies SparingVision and InnoSkel, respectively in the fields of ophthalmology and rare skeletal disorders, Dutch biotech Neogene Therapeutics in solid tumors, and recently Pulmocide in respiratory diseases, based in the UK.

Alentis is led by a highly experienced management team from the biotech and pharma industries. The Company’s science is based on more than 10 years of research by founder Thomas Baumert, a world class hepatology expert who currently serves as the head of Inserm’s Institute of Viral and Liver Diseases. Prof. Baumert’s research in Claudin-1 is unique and, until now, has not been explored as a potential treatment target for fibrotic diseases.

Rafaèle Tordjman, founder and CEO of Jeito, said:Our investment in Alentis at this pivotal time of development will be crucial for its success and we are looking forward to working closely alongside their very experienced team. Our expertise lies in helping management teams from the science right through to commercialization of the product and here we will aim to accelerate Alentis’ efforts towards the initiation of the company’s first clinical trials. This represents our fifth investment in our diverse portfolio and strengthens our commitment to investing in European biotechs working towards the development of lifesaving assets targeted at diseases with unmet need based on outstanding science.

Dr. Roberto Iacone, Chief Executive Officer at Alentis Therapeutics, said: “We are delighted to have closed this financing round with new investors Jeito Capital and Morningside Venture Investments, two well respected and highly knowledgeable institutions within the healthcare space who will bring invaluable experience to the Board as we progress towards the initiation of our first clinical trials. Building on 20 years of work and positive preclinical data collected on ALE.F02, we are confident in the success of the upcoming trials as we work with both new and existing investors towards commercialization, providing a much needed safe and effective treatment to patients suffering from fibrotic diseases and hepatobiliary cancers.”

About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.

About Alentis Therapeutics
Alentis Therapeutics is a Swiss-based biotech that focuses on developing breakthrough treatments for fibrotic diseases. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

The company’s lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung. These represent very large and expanding markets with high unmet need. Furthermore, the company uses a patient-derived drug and target discovery platform to develop medicines for advanced fibrosis.

Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression.

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.

For more information, visit https://alentis.ch/

For more information please contact:

Jeito Capital

Rafaèle Tordjman, Founder and CEO

contact@jeito.life

Consilium Strategic Communications

Mary-Jane Elliott / Melissa Gardiner / Davide Salvi / Kris Lam

Jeito@consilium-comms.com

Tel: + 33 (0) 6 35 36 35 00

Tel: +44 (0) 20 3709 5700

LeddarTech Makes a Welcome Return to In-Person Events as a Lead Sponsor and Exhibitor at Tech.AD 2021 in Berlin, Germany

The Westfield AutoSweep POD

Westfield’s AutoSweep POD, the UK’s first fully autonomous pure electric road sweeper, featuring LeddarTech’s Leddar Pixell.

LeddarTech joins Tech.AD Europe as the Lead Sponsor and as both a presenter and exhibitor at this live event at the Titanic Chaussee Berlin, Germany, on July 1-2, 2021. Join LeddarTech either in person or digitally by registering today at autonomous-driving-berlin.com.

QUEBEC CITY, June 15, 2021 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in Level 1-5 ADAS and AD sensing technology, is excited to be reigniting its physical event calendar as a lead sponsor and keynote speaker of Tech.AD. Tech.AD has long been recognized as one of Europe’s leading technical ADAS and AD conferences. LeddarTech’s CTO Pierre Olivier will serve on the honorary jury for the 8th Annual Tech.AD Europe Awards. These awards honor individuals and organizations who have designed exceptional solutions or products that contribute to ADAS/AD automotive development.

With a focus on environmental sensing that reimagines ADAS and AD solutions, the LeddarTech team will be participating in several capacities at this event.

Keynote presentation: July 1, 2021, 4:45 p.m. – 5:05 p.m. CET

Topic: Sensing Modalities, Sensor Fusion, and Perception for Autonomous Driving. The speaker, Pierre Olivier, Chief Technology Officer of LeddarTech, will explore the challenges and exciting opportunities facing the ADAS and AD business community.

World Café session: July 2, 2021, 1:15 p.m. – 3:35 p.m. CET

Topic: Sensor Café – Object Fusion vs. Raw Sensor Fusion – What Is the Superior Solution? Moderators: Reza Rashidi Far, PhD, and André Malz, PhD, of LeddarTech’s Strategic Product Management division.

Exhibition booth (6): July 1-2, 2021.

LeddarTech will feature solutions that solve critical sensing and perception challenges across the automotive and mobility value chain. LeddarTech will present these solutions through an innovative approach of on-site and live-streaming demonstrations of:

  • Mobility and ITS sensors, including the recently released Leddar™ Sight LiDAR and the award-winning Leddar™ Pixell;
  • LeddarVision™, a sensor-fusion and perception solution that delivers highly accurate 3D environmental models for L1-5 autonomy;
  • Special Feature: the Westfield AutoSweep, the UK’s first fully autonomous pure electric road sweeper, featuring the Leddar Pixell.
The Westfield AutoSweep POD

Westfield’s AutoSweep POD, the UK’s first fully autonomous pure electric road sweeper, featuring LeddarTech’s Leddar Pixell.

“Our technical teams from Israel, Germany, and Italy are excited to be joining our esteemed colleagues, peers, and partners at Tech.AD. Our much-anticipated return to in-person events is especially significant as we will be showcasing our customer Westfield’s autonomous AutoSweep POD, which features the Leddar Pixell,” stated Daniel Aitken, Vice-President, Global Marketing, Communications, and Product Management at LeddarTech. “Tech.AD provides an excellent opportunity to engage with many leaders in the industry both virtually and in person, and we look forward to demonstrating our latest technology, sharing our vision, and engaging with our customers,” Mr. Aitken continued. “Tech.AD is making all efforts to implement precautions to ensure a safe and fulfilling event for all delegates, and I welcome you to visit us in person or online during the event in July,” concluded Mr. Aitken.

For more information about Tech.AD, visit autonomous-driving-berlin.com.

Prior to Tech.AD register for the Automotive IQ Webinar: June 29, 2021, 11:00 a.m. – 12:00 p.m. ET

Topic: A Clean Sweep: How Adopting Autonomous Vehicle and EV Technology Is Paving the Way to Increased Road Sweeper Efficiency and Safety While Reducing Environmental Impact. Join Pierre Olivier, CTO of LeddarTech and Julian Turner, CEO of Westfield Technology Group, for this Automotive IQ hosted event.

Register here.

About LeddarTech

LeddarTech is a leader in environmental sensing platforms for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end-to-end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments. With its LeddarVision™ sensor-fusion and perception platform and its cost-effective, scalable, and versatile LiDAR development solution for automotive-grade solid-state LiDARs based on the LeddarEngine™, LeddarTech enables Tier 1-2 automotive system integrators to develop full-stack sensing solutions for autonomy level 1 to 5. These solutions are actively deployed in autonomous shuttles, trucks, buses, delivery vehicles, smart cities/factories, and robotaxi applications. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 95 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications, and Product Management, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision, and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/2f336faf-ccca-4167-939e-c1dfcfc4c897

https://www.globenewswire.com/NewsRoom/AttachmentNg/84aebadf-f893-466e-8144-9b31e4d79c26

LeddarTech กลับคืนสู่งานอีเว้นท์แบบพบปะรวมตัวในฐานะผู้สนับสนุนหลักและผู้จัดแสดงที่งาน Tech.AD 2021 ในกรุงเบอร์ลิน ประเทศเยอรมนี

Westfield AutoSweep POD

AutoSweep POD ของ Westfield เป็นรถกวาดถนนไฟฟ้าแบบไร้คนขับอัตโนมัติเต็มรูปแบบเครื่องแรกของสหราชอาณาจักร ที่ใช้งาน Leddar Pixell ของ LeddarTech

LeddarTech เข้าร่วมงาน Tech.AD Europe ในฐานะผู้สนับสนุนหลักและเป็นทั้งผู้นำเสนอและผู้จัดแสดงในงานอีเว้นท์สดนี้ที่ Titanic Chaussee Berlin ประเทศเยอรมนี ในวันที่ 1-2 กรกฎาคม 2021 พบกับ LeddarTech ทั้งแบบพบกันตัวต่อตัวหรือแบบดิจิทัลโดยลงทะเบียนวันนี้ที่ autonomous-driving-berlin.com

ควิเบก ซิตี้, June 15, 2021 (GLOBE NEWSWIRE) — LeddarTech® ผู้นำระดับโลกด้านเทคโนโลยีการตรวจจับ ADAS และ AD ระดับ 1-5 รู้สึกตื่นเต้นที่จะได้กลับมาร่วมงานในสถานที่จริงอีกครั้งในฐานะผู้สนับสนุนหลักและผู้บรรยายหลักของงาน Tech.AD โดยงาน Tech.AD ได้รับการยอมรับว่าเป็นหนึ่งในการประชุม ADAS และ AD ด้านเทคนิคชั้นนำของยุโรป Pierre Olivier, CTO ของ LeddarTech จะทำหน้าที่เป็นคณะกรรมการตัดสินกิตติมศักดิ์สำหรับรางวัล Tech.AD Europe ประจำปีครั้งที่ 8 รางวัลเหล่านี้มอบเป็นเกียรติแก่บุคคลและองค์กรที่ออกแบบโซลูชันหรือผลิตภัณฑ์ที่โดดเด่นซึ่งมีส่วนช่วยในการพัฒนายานยนต์ ADAS/AD

ด้วยการมุ่งเน้นไปที่การตรวจวัดสภาพแวดล้อมที่จะกำหนดอนาคตโซลูชัน ADAS และ AD ทีม LeddarTech จะเข้าร่วมงานนี้ในหลายๆ ส่วน

การนำเสนอที่สำคัญ: 1 กรกฎาคม 2021, 16:45 น. – 17:05 น. CET

หัวข้อ: รูปแบบการตรวจจับ การรวมสัญญาณเซ็นเซอร์ และการรับรู้สำหรับการขับขี่อัตโนมัติ ผู้บรรยาย Pierre Olivier หัวหน้าเจ้าหน้าที่ฝ่ายเทคโนโลยีของ LeddarTech จะสำรวจความท้าทายและโอกาสที่น่าตื่นเต้นที่ชุมชนธุรกิจ ADAS และ AD ต้องเผชิญ

เซสชัน World Café: 2 กรกฎาคม 2021, 13:15 น. – 15:35 น. CET

หัวข้อ: Sensor Café – Object Fusion กับ Raw Sensor Fusion – อะไรคือโซลูชันที่เหนือกว่า ผู้ดำเนินการ: Reza Rashidi Far, PhD และ André Malz, PhD, แผนกการจัดการผลิตภัณฑ์เชิงกลยุทธ์ของ LeddarTech

บูธนิทรรศการ (6): 1-2 กรกฎาคม 2021

LeddarTech จะนำเสนอโซลูชันที่ช่วยแก้ปัญหาการตรวจจับและการรับรู้ที่สำคัญทั่วทั้งห่วงโซ่คุณค่ายานยนต์และการเคลื่อนที่ LeddarTech จะนำเสนอโซลูชันเหล่านี้ผ่านแนวทางที่ล้ำสมัยของการสาธิตในงานและการสตรีมสดของ:

  • เซ็นเซอร์การเคลื่อนที่และ ITS รวมถึง Leddar™ Sight LiDAR ที่เปิดตัวเมื่อไม่นานมานี้และ Leddar™ Pixell ที่ได้รับรางวัล
  • LeddarVision™ โซลูชันการรวมสัญญาณและการรับรู้ที่มอบแบบจำลองสภาพแวดล้อม 3 มิติที่แม่นยำสูงสำหรับยานยนต์อัตโนมัติระดับ 1-5
  • หัวข้อเด่น: Westfield AutoSweep รถกวาดถนนไฟฟ้าแบบไร้คนขับอัตโนมัติเต็มรูปแบบคันแรกของสหราชอาณาจักร ที่ใช้ Leddar Pixell
Westfield AutoSweep POD

AutoSweep POD ของ Westfield เป็นรถกวาดถนนไฟฟ้าแบบไร้คนขับอัตโนมัติเต็มรูปแบบเครื่องแรกของสหราชอาณาจักร ที่ใช้งาน Leddar Pixell ของ LeddarTech

“ทีมเทคนิคของเราจากอิสราเอล เยอรมนี และอิตาลีรู้สึกตื่นเต้นที่จะได้ร่วมงานกับเพื่อนร่วมงาน เพื่อนๆ และพันธมิตรที่งาน Tech.AD การกลับมาเข้าร่วมกิจกรรมแบบพบปะตัวต่อตัวที่เราตั้งตารอนั้นมีความสำคัญอย่างยิ่ง เนื่องจากเราจะจัดแสดง AutoSweep POD อัตโนมัติของ Westfield ซึ่งใช้ Leddar Pixell ต่อลูกค้าของเรา” Daniel Aitken รองประธานฝ่ายการตลาด การสื่อสาร และการจัดการผลิตภัณฑ์ระดับโลกของ LeddarTech กล่าว “Tech.AD มอบโอกาสที่ยอดเยี่ยมในการมีส่วนร่วมกับผู้นำจำนวนมากในอุตสาหกรรม ทั้งแบบเสมือนจริงและแบบตัวต่อตัว และเราหวังว่าจะได้สาธิตเทคโนโลยีล่าสุด แบ่งปันวิสัยทัศน์ และมีส่วนร่วมกับลูกค้าของเรา” Mr. Aitken ได้กล่าวต่อ “Tech.AD พยายามอย่างเต็มที่ในการนำมาตรการป้องกันมาใช้เพื่อให้แน่ใจถึงความปลอดภัยและความพึงพอใจของตัวแทน และเราเชิญให้คุณมาเยี่ยมเราด้วยตัวคุณเองหรือแบบออนไลน์ระหว่างการจัดงานในเดือนกรกฎาคม” Mr. Aitken กล่าวสรุป

สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Tech.AD โปรดไปที่ autonomous-driving-berlin.com

ลงทะเบียนเข้าร่วมการสัมมนาออนไลน์ Automotive IQ ก่อนงาน Tech.AD: 29 มิถุนายน 2021, 11:00 น. – 12:00 น. ET

หัวข้อ: A Clean Sweep: การนำเทคโนโลยียานยนต์ไร้คนขับและเทคโนโลยี EV มาใช้เป็นการปูทางไปสู่การเพิ่มประสิทธิภาพและความปลอดภัยของรถกวาดถนนพร้อมทั้งลดผลกระทบต่อสิ่งแวดล้อมได้อย่างไร พบกับ Pierre Olivier, CTO ของ LeddarTech และ Julian Turner, CEO ของ Westfield Technology Group สำหรับงาน Automotive IQ ที่จัดขึ้นมานี้

ลงทะเบียนที่นี่

เกี่ยวกับ LeddarTech

LeddarTech เป็นผู้นำในด้านแพลตฟอร์มการตรวจจับสภาพแวดล้อมสำหรับยานยนต์อัตโนมัติและระบบช่วยเหลือผู้ขับขี่ขั้นสูง LeddarTech ก่อตั้งในปี 2007 โดยได้พัฒนาเป็นบริษัทการตรวจจับสภาพแวดล้อมแบบครบวงจรโดยให้ลูกค้าสามารถแก้ไขปัญหาการตรวจจับและการรับรู้ที่สำคัญได้ทั่วทั้งห่วงโซ่คุณค่าของตลาดยานยนต์และการเคลื่อนที่ ด้วยแพลตฟอร์มการรวมสัญญาณเซ็นเซอร์และการรับรู้ของ LeddarVision™ และโซลูชันการพัฒนา LiDAR ที่คุ้มค่า ปรับขนาดได้ และอเนกประสงค์ LiDAR แบบโซลิดสเตตระดับยานยนต์ที่ใช้งาน LeddarEngine™ ทำให้ LeddarTech ช่วยให้ผู้วางระบบยานยนต์ระดับ Tier 1-2 พัฒนาโซลูชันการตรวจจับแบบครอบคลุมทั้งหมดสำหรับยานยนต์อัตโนมัติระดับ 1 ถึง 5 โซลูชันนี้ได้รับการปรับใช้ในการใช้งานรถรับส่งขับขี่อัตโนมัติ รถบรรทุก รถโดยสารประจำทาง รถส่งสินค้า เมือง/โรงงานอัจฉริยะ และแท็กซี่ไร้คนขับ บริษัทเป็นผู้รับผิดชอบในการคิดค้นนวัตกรรมใหม่ๆ ในแอปพลิเคชันตรวจจับยานยนต์และการเคลื่อนที่ระยะไกลที่ทันสมัยด้วยเทคโนโลยีที่จดสิทธิบัตรมากกว่า 95 รายการ (จดสิทธิบัตรแล้วหรือรอดำเนินการ) ที่ช่วยเสริมขีดความสามารถ ADAS และการขับขี่แบบอัตโนมัติ

สามารถดูข้อมูลเพิ่มเติมเกี่ยวกับ LeddarTech ได้ที่ www.leddartech.com และบน LinkedInTwitterFacebook และ YouTube

ติดต่อ:
Daniel Aitken รองประธานฝ่ายการตลาด การสื่อสารและการจัดการผลิตภัณฑ์ระดับโลก LeddarTech Inc.
โทร: + 1-418-653-9000 ต่อ 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision และโลโก้ที่เกี่ยวข้องเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนของ LeddarTech Inc. และบริษัทในเครือ แบรนด์ ชื่อผลิตภัณฑ์ และเครื่องหมายต่างๆ ทั้งหมดเป็นหรืออาจเป็นเครื่องหมายการค้าที่ใช้เพื่อระบุถึงผลิตภัณฑ์หรือบริการต่างๆ ของเจ้าของที่เกี่ยวข้อง

สามารถรับชมรูปภาพประกอบของการแถลงนี้ได้ที่:

https://www.globenewswire.com/NewsRoom/AttachmentNg/2f336faf-ccca-4167-939e-c1dfcfc4c897/th

https://www.globenewswire.com/NewsRoom/AttachmentNg/84aebadf-f893-466e-8144-9b31e4d79c26/th

BNPB transfers control of self-isolation facilities to local govts

Jakarta (ANTARA) – The National Disaster Mitigation Agency (BNPB) has transferred the management of self-isolation facilities for COVID-19 patients operated out of hotels, inns, and guesthouses to local governments to ensure they are run effectively and efficiently.

Self-isolation facilities managed by the central government or the BNPB will now be controlled by local governments, head of health handling at the COVID-19 Task Force, Alexander K Ginting, said.

“Management at the local government (level) will be more efficient and effective because it can directly touch the root of the problem of isolating residents who are positive for COVID-19,” Ginting told ANTARA in Jakarta on Tuesday.

Though they will now be managed by local governments, the central government will continue to bear the cost of operating the self-isolation facilities in hotels, inns, and guesthouses, he added.

The transfer of control of the management of the self-isolation facilities to local governments would be carried out in stages, he informed.

According to Ginting, the process of transferring control of self-isolation facilities to the local government in DKI Jakarta began on Tuesday.

The DKI Jakarta provincial government has prepared 29 isolation centers for residents affected by COVID-19 and six facilities for health workers from referral hospitals handling coronavirus infections.

In East Java’s Bangkalan, the local government has prepared six hospitals to handle COVID-19 patients, Ginting said.

The regional governments in Kudus (Central Java) and Medan (North Sumatra) have also prepared health and quarantine facilities to tackle the spread of COVID-19 in their respective regions, he added.

According to him, local governments have demonstrated their capability in handling COVID-19 patients.

“If there is a need for central support, there will be coordination,” he added.

However, in managing self-isolation facilities, local governments must still refer to the provisions set by the central government, he said. (INE)

Source: Antara News

31 million COVID-19 vaccine doses administered in Indonesia: minister

Jakarta (ANTARA) – As many as 31 million doses of COVID-19 vaccines were administered countrywide until now, and the vaccination drive was yet underway and being expedited, Coordinating Economic Affairs Minister Airlangga Hartarto stated.

“What we have to do is to accelerate the vaccination drive, as we have already administered 31 million doses,” Hartarto remarked while speaking at a webinar here on Tuesday.

The minister highlighted President Joko Widodo’s envisioned target for one million shots to be administered daily in Indonesia from July 2021.

“We are optimistic that in July, the number (vaccine jabs administered per day) would reach one million, as nothing else can handle COVID-19 except for accelerating vaccination,” he remarked.

Some 600 jabs are expected to be offered by regional health offices and the health ministry, while the remaining 400 jabs will be administered by trained personnel of the Indonesian Defense Forces (TNI) and the Indonesian Police (Polri). Currently, the number of confirmed COVID-19 cases in Indonesia rose by six percent, still better than the global hike of 6.9 percent, according to the minister.

Meanwhile, Hartarto noted that Indonesia’s recovery rate was also at 91.2 percent while the global level reached 91 percent.

However, the government will continue to closely monitor developments in COVID-19 cases following findings of aggressive delta variants in Bangkalan and Kudus.

The government has also decided to extend the implementation of micro-scale community activity restrictions (PPKM) until June 28, 2021, especially in red zones across 34 Indonesian provinces.

Source: Antara News

Wisma Atlet Kemayoran receives 425 COVID-19 patients in 24 hours

Jakarta (ANTARA) – The Wisma Atlet Kemayoran emergency hospital received 425 new COVID-19 patients over the course of the past 24 hours, as Jakarta reels from a post Eid al-Fitr COVID-19 case surge.

Thus, as of Tuesday, a total of 5,453 mildly symptomatic patients were hospitalized at this COVID-19 emergency hospital.

“On Monday, the total number of patients currently hospitalized still stood at 5,028,” Joint Defense Area Command I (Kogabwilhan I) spokesman Colonel Aris Mudian noted.

The patients occupy the hospital beds at Towers 4, 5, 6, and 7, Mudian remarked, adding that 2,484 beds were still vacant as of Tuesday.

Since becoming officially operational on March 23, 2020, this emergency hospital has cumulatively received 92,278 patients.

Of the total tally, 85,815 patients made a complete recovery, 918 patients were sent to several referral hospitals, while 92 others succumbed to the disease, he remarked.

Meanwhile, the Wisma Atlet Pademangan emergency hospital is still offering treatment to 3,326 patients accommodated at Towers 8, 9, and 10, the spokesman noted.

Over these past few days, the Jakarta provincial government had recorded a significant spike in COVID-19 cases.

Jakarta Governor Anies Baswedan had earlier attributed the recent spike in coronavirus infections in the capital city to the Eid al-Fitr holidays.

Baswedan noted that the number of COVID-19 cases had soared to 17,400 on June 11, 2021, from 11,500 on June 6, 2021, thereby indicative of a 50-percent increase in infections.

The COVID-19 positivity rate also climbed to 17 percent on Sunday, from nine percent a week earlier.

The number of specimens tested at laboratories also rose eight folds, as against the WHO-prescribed four-fold increase, he noted.

As a precautionary measure against deteriorating conditions, the Jakarta provincial government has readied 2,500 beds at the Nagrak low-cost apartments in the Cilincing neighborhood of North Jakarta for COVID-19 patients.

The Nagrak apartments will only be used in the event of a steady inflow of new COVID-19 patients at the Wisma Atlet Kemayoran emergency hospital, Baswedan had remarked early this week.

Currently, the Jakarta provincial administration is prioritizing the Wisma Atlet emergency hospital for receiving COVID-19 patients, though Baswedan has called on Jakartans to desist from undermining the recent increase in COVID-19 cases.

Source: Antara News

Widodo asks Jakarta to ramp up vaccinations as infections soar

Jakarta (ANTARA) – President Joko Widodo has asked the Jakarta administration to speed up COVID-19 vaccinations amid a surge in cases, chief of the Jakarta Provincial Legislative Assembly (DPRD), Prasetyo Edi Marsudi, said.

The vaccination program in ports and densely populated areas must be expedited, Marsudi told the press at the Presidential Palace here on Tuesday.

President Widodo on Tuesday summoned the Jakarta Regional Leadership Communication Forum (Forkopimda) and issued directives on ways to deal with a recent spike in COVID-19 cases.

Besides DPRD chief Marsudi, the forum comprised Jakarta Governor Anies Baswedan, Commander of the Jakarta Regional Military Command, Major General Mulyo Aji, chief of the Jakarta Metropolitan Police, Inspector General Fadil Imran, and mayors and resort police chiefs from across Jakarta.

The President noted that COVID-19 cases in Jakarta have increased sharply, with one of the causes being the entry of a new variant from India.

“The President has asked us as the regional apparatuses to curb (COVID-19 transmission),” Marsudi said. The President has also asked Forkopimda members to make field visits to aid greater public compliance with health protocols, he added.

Governor Baswedan had earlier attributed the spike in coronavirus infections in the capital to the Eid al-Fitr holidays.

Jakarta should accord greater attention to the sharp jump in COVID-19 cases in the past week, he said during a roll call held on Sunday night to remind agencies of their obligation to stem the spread of COVID-19.

There has been a 50-percent increase in infections in the capital city, with the number of cases climbing to 17,400 on June 11, 2021 from 11,500 on June 6, 2021, he observed.

The COVID-19 positivity rate also increased to 17 percent on Sunday from 9 percent a week earlier.

“The number of new cases increased in each of the past four days by 2,000, 2,300, 2,400, and 2,700 today,” Baswedan noted.

The number of specimens tested at laboratories also increased eight-fold as against a four-fold increase prescribed by the WHO.

Source: Antara News

COVID-19: Six Java provinces see post-Eid surge

Jakarta (ANTARA) – The national COVID-19 task force has recorded a post Eid al-Fitr spike in coronavirus infections in Jakarta, Banten, West Java, Central Java, Yogyakarta, and East Java provinces this week.

“The top five highest increases in COVID-19 cases have been found in the provinces of Jakarta, Central Java, West Java, Yogyakarta, and East Java,” task force spokesperson Wiku Adisasmito informed at an online press conference that ANTARA joined from Jakarta on Tuesday.

The sixth biggest contributor to the latest COVID-19 surge has been Banten province, he added.

The six provinces, which are all located on Java Island, have recorded between four hundred and seven thousand cases this week, he disclosed.

The post Eid al-Fitr COVID-19 surge has been observed in Central Java, East Java, Yogyakarta, and Banten as they received homebound travelers during this year’s Eid holiday season, he said.

Jakarta, too, is facing an increase in cases due to homeward-bound travelers, he added.

The government and communities must pay serious attention to this worrisome situation, he said and urged regional governments to implement control strategies.

“Our focus is how to control the case surge in the hardest-hit regions, and to (ensure people) comply with health protocols and mobility restrictions for domestic and overseas trips,” Adisasmito said.

Over the past few days, the Jakarta provincial government has recorded a significant increase in COVID-19 cases.

Jakarta Governor Anies Baswedan has attributed the recent spike in coronavirus infections in the capital city to the Eid al-Fitr holidays.

There has been a 50-percent increase in infections, with the number of COVID-19 cases rising to 17,400 on June 11, 2021 from 11,500 on June 6, 2021, he noted.

The COVID-19 positivity rate also increased to 17 percent on Sunday from 9 percent the previous week.

The number of specimens tested at laboratories also rose eight-fold, as against the WHO-prescribed four-fold increase, he noted.

As a precautionary measure, the Jakarta provincial government has prepared 2,500 beds at the Nagrak low-cost apartments in Cilincing neighborhood of North Jakarta for COVID-19 patients.

The Nagrak apartments will only be used if the Wisma Atlet Kemayoran emergency hospital continues to receive new COVID-19 patients, Baswedan said on Monday.

Currently, the Jakarta provincial administration is prioritizing the Wisma Atlet emergency hospital for receiving COVID-19 patients, said Baswedan.

He also urged Jakartans to not undermine the recent increase in COVID-19 cases. (INE)

Source: Antara News